| Message: | Product Name: Raloxifene
Alias: Evista
CAS: 84449-90-1
Molecular Formula: C28H27NO4S
Molecular Weight: 473.58
Purity: 99%
Grade: Pharmaceutical Grade
Appearance: Light Yellow Powder
Oral SERM
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
Specifically, Raloxifene is a non-steroidal SERM belonging to the benzothiophene family. Raloxifene is very similar in its mode of action as Nolvadex (Tamoxifen), and does exhibit both Estrogen agonist as well as Estrogen antagonist effects in different tissues throughout the body. In particular, Raloxifene serves as an Estrogen antagonist in breast tissue and uterine tissue while at the same time acting as an Estrogen agonist in bone tissue. Raloxifene is in fact utilized in medicine in the prevention of osteoporosis in post-menopausal females due to its estrogenic activity in bone. In contrast, Nolvadex is known to act as an Estrogen antagonist in bone, which obviously presents a problem for female breast cancer patients who have been prescribed the use of Nolvadex. Considering these properties, it is therefore understandable why Raloxifene had demonstrated some clear advantages over Nolvadex, and has proven itself as a novel new drug in the treatment of various post-menopausal diseases in female patients.
|
my account
